310 related articles for article (PubMed ID: 33910078)
1. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
[TBL] [Abstract][Full Text] [Related]
2. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study.
Ibrahim TS; Almalki AJ; Moustafa AH; Allam RM; Abuo-Rahma GEA; El Subbagh HI; Mohamed MFA
Bioorg Chem; 2021 Jun; 111():104885. PubMed ID: 33838559
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking, discovery, synthesis, and pharmacological properties of new 6-substituted-2-(3-phenoxyphenyl)-4-phenyl quinoline derivatives; an approach to developing potent DNA gyrase inhibitors/antibacterial agents.
Alagumuthu M; Arumugam S
Bioorg Med Chem; 2017 Feb; 25(4):1448-1455. PubMed ID: 28094220
[TBL] [Abstract][Full Text] [Related]
4. New 1,2,4-oxadiazole/pyrrolidine hybrids as topoisomerase IV and DNA gyrase inhibitors with promising antibacterial activity.
Frejat FOA; Cao Y; Wang L; Zhai H; Abdelazeem AH; Gomaa HAM; Youssif BGM; Wu C
Arch Pharm (Weinheim); 2022 Jul; 355(7):e2100516. PubMed ID: 35363388
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors.
Durcik M; Tammela P; Barančoková M; Tomašič T; Ilaš J; Kikelj D; Zidar N
ChemMedChem; 2018 Jan; 13(2):186-198. PubMed ID: 29206345
[TBL] [Abstract][Full Text] [Related]
6. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C
Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977
[TBL] [Abstract][Full Text] [Related]
7. Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV.
Metwally NH; Abdallah SO; Mohsen MMA
Bioorg Chem; 2020 Apr; 97():103672. PubMed ID: 32145481
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
9. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Evaluation of Novel Tyrosine-Based DNA Gyrase B Inhibitors.
Cotman AE; Trampuž M; Brvar M; Kikelj D; Ilaš J; Peterlin-Mašič L; Montalvão S; Tammela P; Frlan R
Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28621824
[TBL] [Abstract][Full Text] [Related]
11. New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
Durcik M; Lovison D; Skok Ž; Durante Cruz C; Tammela P; Tomašič T; Benedetto Tiz D; Draskovits G; Nyerges Á; Pál C; Ilaš J; Peterlin Mašič L; Kikelj D; Zidar N
Eur J Med Chem; 2018 Jun; 154():117-132. PubMed ID: 29778894
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
Gjorgjieva M; Tomašič T; Barančokova M; Katsamakas S; Ilaš J; Tammela P; Peterlin Mašič L; Kikelj D
J Med Chem; 2016 Oct; 59(19):8941-8954. PubMed ID: 27541007
[TBL] [Abstract][Full Text] [Related]
13. Development and radiosterilization of new hydrazono-quinoline hybrids as DNA gyrase and topoisomerase IV inhibitors: Antimicrobial and hemolytic activities against uropathogenic isolates with molecular docking study.
Ammar YA; Micky JA; Aboul-Magd DS; Abd El-Hafez SMA; Hessein SA; Ali AM; Ragab A
Chem Biol Drug Des; 2023 Feb; 101(2):245-270. PubMed ID: 36305722
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives.
El-Shershaby MH; El-Gamal KM; Bayoumi AH; El-Adl K; Ahmed HEA; Abulkhair HS
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000277. PubMed ID: 33078877
[TBL] [Abstract][Full Text] [Related]
15. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Mitton-Fry MJ; Brickner SJ; Hamel JC; Brennan L; Casavant JM; Chen M; Chen T; Ding X; Driscoll J; Hardink J; Hoang T; Hua E; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Plotkin M; Reilly U; Robinson S; Schafer J; Shepard RM; Smith JF; Stone GG; Subramanyam C; Yoon K; Yuan W; Zaniewski RP; Zook C
Bioorg Med Chem Lett; 2013 May; 23(10):2955-61. PubMed ID: 23566517
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization, theoretical, anti-bacterial and molecular docking studies of quinoline based chalcones as a DNA gyrase inhibitor.
Abdullah MI; Mahmood A; Madni M; Masood S; Kashif M
Bioorg Chem; 2014 Jun; 54():31-7. PubMed ID: 24747187
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
Alt S; Mitchenall LA; Maxwell A; Heide L
J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects.
Ibrahim NM; Fahim SH; Hassan M; Farag AE; Georgey HH
Eur J Med Chem; 2022 Jan; 228():114021. PubMed ID: 34871841
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities.
Aziz HA; El-Saghier AMM; Badr M; Abuo-Rahma GEA; Shoman ME
Mol Divers; 2022 Jun; 26(3):1743-1759. PubMed ID: 34455532
[TBL] [Abstract][Full Text] [Related]
20. New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.
Durcik M; Nyerges Á; Skok Ž; Skledar DG; Trontelj J; Zidar N; Ilaš J; Zega A; Cruz CD; Tammela P; Welin M; Kimbung YR; Focht D; Benek O; Révész T; Draskovits G; Szili PÉ; Daruka L; Pál C; Kikelj D; Mašič LP; Tomašič T
Eur J Med Chem; 2021 Mar; 213():113200. PubMed ID: 33524686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
